Besivance Suspension
NDC Package 24208-446-02

11-digit billing NDC: 24208044602

Package Information

Besivance (besifloxacin) suspension is bESIVANCE ®(besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*CDC coryneform group GCorynebacterium pseudodiphtheriticum*Corynebacterium striatum*Haemophilus influenzaeMoraxella catarrhalis*Moraxella lacunata*Pseudomonas aeruginosa*Staphylococcus aureusStaphylococcus epidermidisStaphylococcus hominis*Staphylococcus lugdunensis*Staphylococcus warneri*Streptococcus mitisgroup Streptococcus oralisStreptococcus pneumoniaeStreptococcus salivarius**Efficacy for this organism was studied in fewer than 10 infections. This formulation utilizes a suspension delivery system. Marketed by Bausch & Lomb Incorporated, this product is identified by NDC 24208-446 and is authorized under FDA application NDA022308.

Identification & Billing

NDC Package Code
24208-446-02
Package Description
1 BOTTLE, DROPPER in 1 CARTON / 2 mL in 1 BOTTLE, DROPPER
Product Code
11-Digit Billing Format
24208044602
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Besivance
Non-Proprietary Name
Besifloxacin
Substance Name
Besifloxacin
Dosage Form
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route
Ophthalmic - Administration to the external eye.
Active Ingredient(s)
Usage Information
BESIVANCE ®(besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*CDC coryneform group GCorynebacterium pseudodiphtheriticum*Corynebacterium striatum*Haemophilus influenzaeMoraxella catarrhalis*Moraxella lacunata*Pseudomonas aeruginosa*Staphylococcus aureusStaphylococcus epidermidisStaphylococcus hominis*Staphylococcus lugdunensis*Staphylococcus warneri*Streptococcus mitisgroup Streptococcus oralisStreptococcus pneumoniaeStreptococcus salivarius**Efficacy for this organism was studied in fewer than 10 infections.

Regulatory & Marketing

Labeler Name
Bausch & Lomb Incorporated
Product Type
Human Prescription Drug
FDA Application #
NDA022308
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
05-28-2009
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (24208-446). Click a package code to view its specific billing and regulatory data.

1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 24208-446-02 identifies a specific commercial package of 1 bottle, dropper in 1 carton / 2 ml in 1 bottle, dropper of Besivance, a human prescription drug labeled by Bausch & Lomb Incorporated. This suspension is formulated for ophthalmic use and contains besifloxacin as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bausch & Lomb Incorporated on May 28, 2009. The current certification is valid through December 31, 2027.

How is this Bausch & Lomb Incorporated product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 24208044602. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
24208-446-02
11-Digit CMS (5-4-2)
24208-0446-02

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.